IRELLI, AZZURRA
 Distribuzione geografica
Continente #
NA - Nord America 396
EU - Europa 318
AS - Asia 124
SA - Sud America 3
OC - Oceania 1
Totale 842
Nazione #
US - Stati Uniti d'America 394
IE - Irlanda 105
DE - Germania 61
IT - Italia 61
CN - Cina 44
SG - Singapore 43
SE - Svezia 34
TR - Turchia 23
UA - Ucraina 14
FI - Finlandia 11
CZ - Repubblica Ceca 10
GB - Regno Unito 10
VN - Vietnam 7
IN - India 6
FR - Francia 4
BR - Brasile 2
CA - Canada 2
BE - Belgio 1
BG - Bulgaria 1
EE - Estonia 1
ES - Italia 1
HR - Croazia 1
HU - Ungheria 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PE - Perù 1
RO - Romania 1
TH - Thailandia 1
Totale 842
Città #
Chandler 102
Dublin 101
Jacksonville 66
Singapore 40
Boardman 38
Munich 18
Izmir 13
L'aquila 13
Princeton 13
Ashburn 12
Berlin 12
Bremen 12
Lawrence 12
New York 12
Brno 10
Nanjing 10
San Mateo 9
Dong Ket 6
Helsinki 6
Wilmington 6
Beijing 5
Civitanova Marche 5
Des Moines 5
Shenyang 5
L’Aquila 4
Norwalk 4
Woodbridge 4
Hebei 3
Los Angeles 3
Milan 3
Pune 3
Redwood City 3
Aquila 2
Dallas 2
Dearborn 2
Kitzingen 2
Mountain View 2
Pescara 2
Rome 2
San Francisco 2
Shanghai 2
Taizhou 2
Tianjin 2
Verona 2
Ann Arbor 1
Arzignano 1
Bangkok 1
Brussels 1
Budapest 1
Cambridge 1
Cologne 1
Fairfield 1
Frankfurt am Main 1
Fremont 1
Grafing 1
Hanoi 1
Hefei 1
Istanbul 1
Kunming 1
Lanciano 1
Lappeenranta 1
Lima 1
Madrid 1
Montesilvano Marina 1
Motueka 1
Nanchang 1
Nuremberg 1
Palermo 1
Qingdao 1
Santa Clara 1
Seattle 1
São Paulo 1
Tallinn 1
Toronto 1
Zagreb 1
Zhengzhou 1
Totale 614
Nome #
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 101
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 100
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 93
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 84
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 69
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 64
Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception 57
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 54
Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting 54
Real-life use of denosumab 120 mg every 12 weeks in prolonged treatment over 2 years of patients with breast cancer bone metastases 48
Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management 46
Effectiveness of restoring vitamin B12 levels in the resolution of a case of erythema nodosum 45
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 39
Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery 13
Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer 9
Totale 876
Categoria #
all - tutte 4.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.211


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202041 0 0 0 0 0 6 13 6 8 0 1 7
2020/2021100 1 7 3 9 13 3 14 4 14 5 18 9
2021/202282 3 0 17 5 0 1 0 3 3 10 6 34
2022/2023300 13 25 1 44 25 26 0 18 129 3 10 6
2023/2024112 7 3 2 2 6 21 1 8 0 3 17 42
2024/202595 11 12 41 20 11 0 0 0 0 0 0 0
Totale 876